NCT07364422Not yet recruitingPhase 1/2
To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer
A Multicenter, Open-label, Single-arm, Dose-finding and Expansion Phase 1b/2 Study to Evaluate the Safety and Tolerability of JPI-547 in Combination With Irinotecan as a Third Line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer
Source: ClinicalTrials.gov · Last updated 23 Jan 2026
Brief summary (registry, in English)
This study aims to evaluate the safety and tolerability of JPI-547 in combination with irinotecan as a third-line and beyond therapy for recurrent or metastatic gastric cancer
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 49 (estimated)
- First submitted
- 11 Jan 2026
- Start date
- 27 Feb 2026
- Primary completion date
- 28 Feb 2026
- Lead sponsor
- Onconic Therapeutics Inc.
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07364422
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 49
- From 27 Feb 2026 to the primary completion date, 28 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with a confirmed specific medical history or past surgical history
- Patients who meet specific criteria regarding prior treatment
- Patients who have undergone major surgery within 4 weeks prior to screening or are expected to require major surgery during the clinical trial are excluded. (However, those who have had minor surgeries
- Patients with symptoms at the time of screening, who have not received treatment, or who have rapidly progressing central nervous system (CNS) metastases.
- Subjects with a history of severe allergic anaphylactic reactions to the investigational product and/or its components, or who have contraindications to the administration of the investigational product and/or irinotecan
Other illness
- Patients with a history of specific drug administration
- Patients with mental disorders or altered mental status/consciousness (AMS) that impair their ability to understand this clinical trial for informed consent.
Other
- Patients with specific comorbidities.
- Pregnant or Lactating Women
- Patients considered unsuitable for this clinical trial by the investigator.
Who the study is looking for
- Patients with recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma who have progressed after second-line therapy.
- Those with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Those with at least one measurable lesion in accordance with RECIST 1.1
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Severance Hospital, Yonsei Cancer Center, Yonsei University College of Medicine Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.